Opus Genetics (IRD) S-4 Registration of securities issued in business combination transactions

Exhibit 99.7

July 6, 2020

Rexahn Pharmaceuticals, Inc.

15245 Shady Grove Road, Suite 455

Rockville, MD 20850

Consent to Reference in Proxy Statement/Prospectus/Information Statement

Rexahn Pharmaceuticals, Inc. (the “Company”) has filed the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the proxy statement/prospectus/information statement included in such registration statement as a future member of the board of directors of the Company.

Sincerely,

/s/ Sean Ainsworth         

Sean Ainsworth